101 related articles for article (PubMed ID: 12959297)
1. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects.
Flouvat B; Delhotal-Landes B; Cournot A; Dellatolas F
Br J Clin Pharmacol; 1993 Nov; 36(5):467-9. PubMed ID: 12959297
[TBL] [Abstract][Full Text] [Related]
2. Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers.
Barclay ML; Begg EJ; Robson RA; Peters WA; Ketelbey JW
Aliment Pharmacol Ther; 1999 Sep; 13(9):1215-9. PubMed ID: 10468704
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of lansoprazole.
Landes BD; Petite JP; Flouvat B
Clin Pharmacokinet; 1995 Jun; 28(6):458-70. PubMed ID: 7656504
[TBL] [Abstract][Full Text] [Related]
4. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between lansoprazole and theophylline.
Granneman GR; Karol MD; Locke CS; Cavanaugh JH
Ther Drug Monit; 1995 Oct; 17(5):460-4. PubMed ID: 8585108
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
Amer F; Karol MD; Pan WJ; Griffin JS; Lukasik NL; Locke CS; Chiu YL
Clin Ther; 2004 Dec; 26(12):2076-83. PubMed ID: 15823771
[TBL] [Abstract][Full Text] [Related]
8. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans.
Katsuki H; Yagi H; Arimori K; Nakamura C; Nakano M; Katafuchi S; Fujioka Y; Fujiyama S
Pharm Res; 1996 Apr; 13(4):611-5. PubMed ID: 8710755
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration.
Mainz D; Borner K; Koeppe P; Kotwas J; Lode H
J Antimicrob Chemother; 2002 Nov; 50(5):699-706. PubMed ID: 12407126
[TBL] [Abstract][Full Text] [Related]
10. High-performance thin-layer chromatographic method for the detection and determination of lansoprazole in human plasma and its use in pharmacokinetic studies.
Pandya KK; Mody VD; Satia MC; Modi IA; Modi RI; Chakravarthy BK; Gandhi TP
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):199-204. PubMed ID: 9200535
[TBL] [Abstract][Full Text] [Related]
11. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
Sohn DR; Kwon JT; Kim HK; Ishizaki T
Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of fast disintegrating lansoprazole tablet in human subjects.
Iwasaki K; Yoshikawa Y; Shibata N; Takada K; Sakurai Y; Takagi N; Irie S; Nakamura K
Drug Metab Pharmacokinet; 2004 Jun; 19(3):227-35. PubMed ID: 15499190
[TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
[TBL] [Abstract][Full Text] [Related]
15. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.
Hussein Z; Granneman GR; Mukherjee D; Samara E; Hogan DL; Koss MA; Isenberg JI
Br J Clin Pharmacol; 1993 Nov; 36(5):391-8. PubMed ID: 12959285
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of lansoprazole in hemodialysis patients.
Karol MD; Machinist JM; Cavanaugh JM
J Clin Pharmacol; 1995 Aug; 35(8):815-20. PubMed ID: 8522639
[TBL] [Abstract][Full Text] [Related]
19. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
20. Lansoprazole pharmacokinetics in subjects with various degrees of kidney function.
Karol MD; Machinist JM; Cavanaugh JM
Clin Pharmacol Ther; 1997 Apr; 61(4):450-8. PubMed ID: 9129562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
